Genexine

제넥신 · 095700

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$115.3M (₩159.2B)

Overview

Genexine is a biopharmaceutical company that researches and develops medicines, including treatments designed to work with the body's immune system, for patients with serious diseases.

Its products and drug candidates are aimed at healthcare providers and patients, and it operates within the broader life-sciences supply chain as a developer of novel therapies. Genexine is listed on KOSDAQ, South Korea's technology and small-cap stock exchange, and is currently in a development-stage phase where it has not yet reached profitability.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$3.3M

▲ +56.0% YoY

Operating profit · FY2025

−US$26.2M

Loss narrowed

Net income · FY2025

−US$19.7M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$3.2M(₩4.4B)	US$2.1M(₩2.9B)	US$3.3M(₩4.6B)
Operating profit	−US$29.9M(−₩41.2B)	−US$27M(−₩37.2B)	−US$26.2M(−₩36.2B)
Net income	−US$48.4M(−₩66.9B)	−US$46.2M(−₩63.7B)	−US$19.7M(−₩27.2B)

Revenue

FY2023US$3.2M
FY2024US$2.1M
FY2025US$3.3M

Operating profit

FY2023−US$29.9M
FY2024−US$27M
FY2025−US$26.2M

Net income

FY2023−US$48.4M
FY2024−US$46.2M
FY2025−US$19.7M

Key ratios (FY2025)

ROE

-11.0%

Debt/Eq

50.5%

Op. margin

-790.8%

Net margin

-595.0%

Rev. YoY

▲ +56.0%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?